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Introduction: Late-onset Pompe disease (LOPD) is a progressive metabolic myopathy, affect-
ing skeletal muscles, which, if untreated, leads to disability and/or respiratory failure. The
enzyme replacement therapy (ERT) improves muscle strength and respiratory function and
prevents disease progression.We present a 6-year follow-up of 5 patients with LOPD treated
with ERT.
Methods: Five patients with LOPD received ERT: two started treatment in 2008, other two in
2010 and one in 2011. All patients received recombinant human alpha-glucosidase in dose
20 mg/kg intravenously every two weeks. Physical performance was assessed in 6-minute
walk test (6MWT) and spirometry was performed to examine FVC and FEV1. Liver enzymes,
CK levels were also assessed.
Results: The walking distance in 6MWT increased by average 16.9  2.26% in the ﬁrst three
years of treatment. Similar changes were detected in spirometry: the most signiﬁcant FVC
increase was observed in two patients with the highest FVC values before treatment, which
increased to normal values adjusted for age and sex in three years of treatment, that is by
28% and 34%. In two other patients FVC reached 88% and 76% of predicted values. ERT also
improved the liver and muscle enzymes levels.
Conclusion: The improvements of exercise tolerance and FVCwere observed in all patients in
the ﬁrst three years of treatment and were the most pronounced in the longest-treated
patients and with the least severe neurological and respiratory symptoms. Our research
suggests that early start of the ERT results in higher improvement of respiratory and
ambulation functions.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.* Corresponding author at: I-st Dept of Neurology, Institute of Psychiatry and Neurology, Sobieskiego 9 str, 02-958 Warsaw, Poland.
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which, due to deﬁciency or absence of enzyme (lysosomal acid
alpha-glucosidase [GAA] or acid maltase) that catalyze the
degradation of glycogen, it accumulates in certain tissues (ﬁrst
in the lysosomes and in the case of their damage by excess of
glycogen, also in the cytoplasm of cells), particularly in
muscles, but also in the heart and other internal organs [1].
Pompe disease is a hereditary autosomal recessive disorder
and its symptoms occur in individuals with two abnormal
copies of the GAA gene. Yet, about 200 different mutations in
GAA gene located on chromosome 17 encoding the GAA
protein have been discovered. Mutations can result in the
complete absence of enzyme or inactive enzyme (which leads
to infantile form of the disease), the correct amount of enzyme
with reduced activity, or to reduced enzyme amount with
normal activity (which leads to late-onset Pompe disease –
LOPD) [2]. Mutation of c.-32-13T>G is most common in late-
onset disease form. This mutation leads to a reduction of GAA
to 10–20% of normal activity [3]. Despite the later age of
symptoms onset and the milder phenotype, adult form of
Pompe disease, if not treated, cause progressive physical
disability with limbs ﬂaccid paralysis. Some patients would
require a wheelchair or respiratory therapy if progressive
respiratory failure occurs.
In Poland, in the years 1999–2012, 37 patients were
diagnosed with Pompe disease: 25 people with early-onset
and 12 patients with late-onset forms of the disease. No
relation to gender was found.
The enzyme replacement therapy (ERT) has been shown to
improve muscle strength and respiratory function and to
prevent disease progression [4]. We present a 6-year follow-up
of 5 patients with LOPD treated with ERT.
2. Materials and methodsFive patients with late-onset Pompe disease receiving enzy-
matic replacement therapy: two sisters (current age 39 and 41),
another female (current age 32) and twomale subjects (current
age 48 and 54) have been observed prospectively (Table 1).
Age range of patients was 26–41 years at the beginning of
treatment, which is consistent with statistic data concerning
symptoms onset, although two youngest patients reported
shortness of breath, especially on exercise, recurrent respira-
tory infections and morning headaches or daytime sleepiness
while they were growing up, which suggest that they mightTable 1 – Basic demographic and clinical data.
Initials Sex Age Age of ﬁrst
symptoms
Age at
diagnosis
Age at the b
of the tre
AG F 32 7 (1991) 25 (2009) 26 (20
DK F 41 25 (2000) 31 (2006) 33 (20
UM F 39 27 (2004) 29 (2006) 31 (20
AF M 48 36 (2004) 40 (2009) 41 (20
ZT M 54 33 (1998) 48 (2011) 48 (20have had juvenile form of Pompe disease. They also
complained on difﬁculties while marching or climbing the
stairs. Above mentioned symptoms (which are secondary to
respiratory muscle involvement, hypoxia and nocturnal
hypoventilation) [5,6] were present in all patients. Two male
patients had already been diagnosed with obstructive sleep
apnea syndrome, which is very common in LOPD [7,8]. They
had been treated with CPAP before Pompe disease diagnosis
was made.
Pompe diseasewas diagnosed as the reasons of progressive
muscle weakness and reduced exercise tolerance in four of
these patients (all female and the oldest male). The youngest
female underwent a detailed diagnostic procedure for liver
diseases (including liver biopsy) before LOPDwas suspected. In
one, diagnosis was made after severe respiratory failure event
of unknown cause. In all patients, the diagnosiswas conﬁrmed
with a genetic test and the assessment of GAA activity in
leucocytes and in dried blood spot (DBS) (Table 2).
In all patients at least 2 pathogenic mutations underlying
Pompe disease were found. In 3 of them genetic testing
conﬁrmed the presence of the above mentioned common
pathogenic mutation c.-32-13T>G. This mutation is responsi-
ble for a splicing defect. The ability to produce the reduced
amount of enzyme is a reason of a relatively mild phenotype
[3,9]. In two sisters the same mutation c.1796C>A was found.
This mutation relatively rarely found among the Caucasian
population was ﬁrstly described in 2008 and also is connected
with non-severe phenotype of the disease [10].
All patients presented with myopathy, proximal muscle
weakness (mainly shoulder and pelvic girdle), hypotonia and
reduced tendon reﬂexes, which severity depended on disease
duration. Excessive lumbar lordosis and thoracic kyphosis
secondary to paraspinal muscle weakness also were visible in
the oldest male patients. Those abnormalities were responsi-
ble for changes in the static properties of thoracic and lumbar
spine and contribute to characteristic waddling gait. None of
the patients had cardiac abnormalities suggesting subclinical
cardiomyopathy and signs of cataract on ophalmological
examination.
FVC before treatment introduction were 77% (AG), 78%
(UM), 61% (DK) and 63% (AF) (results adjusted for age and sex),
consistently with previous observations suggesting that in
about 60% of patients with late-onset Pompe disease FVC is of
<80% of predicted value, with the remaining 30–40% – down to
<60% of predicted [11,12]. Forced expiratory volume in one
second (FEV1)was also decreased in all patients (Fig. 1A and B).
Further tests showed increased activity of creatine kinase
(CK) and creatine kinase MB (CK-MB) (Fig. 1C), which are
indicators of muscle damage, and increased activity ofeginning
atment
Time of the
treatment
Time from the beginning
of symptoms to the start of ERT
10) 6 19
08) 8 8
08) 8 4
10) 6 5
11) 5 16
Table 2 – Results of genetic testing and GAA activitya before ERT introduction.
Patient (sex/age) Pathogenic mutation. GAA activity in leukocytes
(norm: 0.31–0.52)
GAA activity in DBS
(norm: 0.29–0.49)
F/32 c.-32-13T>G, c.307T>G 0.07 n.d.
F/39 c.1796C>T, c.364A>G 0.09 0.12
F/41 c.1796C>T, c.364A>G 0.07 0.05
M/48 c.-32-13T>G, c307T>C 0.07 n.d.
M/54 c.-32-13T>G, c.307T>G n.d. n.d.
a GAA activity ratios measured at pH 3.8 with and without acarbose.
n.d. – not done.
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ferase (A1AT), which indicate a subclinical liver damage [13]
(Fig. 2). The levels of these abnormalities varied among
patients and no relation was found between CK/AspAT/AlAT
levels and patient's age (disease duration), their everyday
activity or additional physical activity.
3. Enzymatic replacement therapyPatients have been treated with recombinant human acid
alpha-glucosidase (rhGAA) in recommended dose of 20 mg/kg
administered intravenously every two weeks. The treatment
was introduced 2 years after diagnosis of Pompe disease in two
siblings and within 1-year in three another patients.
ERT overall tolerability was good. Two patients suffered
from muscle pain in lower limbs lasting a 2–3 months after[(Fig._1)TD$FIG]
Fig. 1 – Changes of mean value of 6MWT (A), FVC (B) and serum l
CK levels for each patient with LOPD at baseline (before the init
treatment. 6MWT – 6 min walking test, FVC – forced vital capaci
therapy, LOPD – late-onset Pompe disease.treatment introduction. All patients reported mild dizziness
for few hours after drug infusion.
4. Treatment monitoringRoutinely careful clinical assessment is carried, and diagnostic
tests are performed every 6 months in patients receiving ERT.
Physical performance is assessed in 6-minute walk test and
spirometry is performed to examine FVCand FEV1. Gasometry,
liver enzymes activity, CK levels are also assessed. ECG and
echocardiography are performed to detect potential cardiac
disease and pulmonary consultation is carried to detect
potential pulmonary abnormalities or diagnose obstructive
sleep apnea syndrome. Ophthalmic, orthopedic and laryngo-
logical examinations serve for early detection of cataract
(which often occurs in patients with Pompe disease) orevel of CK (C) observed during the 6-years ERT treatment. (D)
iation of the ERT treatment), in the 2nd and 6th year of the
ty, CK – creatine kinase, ERT – enzymatic replacement
[(Fig._2)TD$FIG]
Fig. 2 – Changes in mean level of AspAt (Aa) and AlAt (Ba) found during the 6-years ERT treatment. AspAt (Ab) and AlAt (Bb)
levels for each patient with LOPD present at baseline (before initiation of ERT treatment) and in the 6th year of treatment.
AspAt – aspartate aminotranspherase, AlAt – alanine aminotranspherase, ERT – enzymatic replacement therapy, LOPD –
late-onset Pompe disease.
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and chest X-ray are also repeated.
5. Treatment resultsThe walking distance assessed by 6MWT increased by average
16.9  2.26% in the ﬁrst three years of treatment (from 507.0
 14.6 m to 591.0  15.5 m), and then tended to stabilize
reaching increase by 19.5  1.33% (606.0  6.8 m) from the
baseline at the end of the 6-years observational period (Fig. 1A).
Similar pattern of changes was detected in the level of CPK,
which signiﬁcant reduction was present after the ﬁrst 2 years
of treatment (34.8  12.26%). During the rest of observational
period stable values of CPK were found with 35.6  14.5%
reduction from baseline after 6 years (Fig. 1C and D). Also, FVC
values increased in the ﬁrst 2 years (23.3  11.2%) and then
tended to improve slowly during the rest of observational
period (31.7  6.7% from baseline after 6 years) (Fig. 1B). The
most signiﬁcant FVC increase was observed in patients with
the highest FVC values before treatment (AG and UM), which
reached normal values adjusted for age and sex in two years of
treatment, that is an improvement by 28% and 34%. In two
other patients FVC increase reached 88% (DK) and 76% (AF) of
predicted values.
Both liver enzymes: aspartate aminotransferase (AspAT)
and alanine aminotransferase (A1AT) levels showed slow, but
continuous reduction during the whole observational period.AspAT after 6 years of observation dropped from 112.8  21.0
to 69.0  10.6 mg/dl (38.0  4.1% reduction). In one patient (AG)
these values reached normal levels (reduction from 66.0 to
44.0 mg/dl) (Fig. 2Aab).
Similarly, AlAT values decreased frommean value of 107.4
 15.4 mg/dl–66.8  14.2 mg/dl (44.6  4.5% reduction from the
baseline levels) (Fig. 2Bab).
Consecutive regular examinations did not reveal any
abnormalities in cardiovascular system, but mild skeletal
abnormalities (scoliosis in 4 patients), liver enlargement (in 1
patient) and cataract (in 1 patient) were found.
During the treatment, all patients maintained their
professional activity, and there were no important clinical
events observed.
6. DiscussionThe increase in the walking distance (which indicates the
improvement of exercise tolerance) was observed in all
patients in the ﬁrst two years of treatment and was the most
prominent in patients with the least severe neurological and
respiratory symptoms. The clinical improvement observed in
the ﬁrst 2 years of treatment seemed to be correlated with
reduction of creatine kinase levels and improvement of
respiratory system function revealed by an increase of FVC.
All abovemeasurements remained stable during the follow-up
period.
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previous studies. In a randomized, placebo-controlled study
done by van der Ploeg et al. [14] during 78-week observation
period the most prominent increase in 6MWT was documen-
ted in ﬁrst 26 weeks and then was followed by stabilization of
the results. The most marked improvement was observed in
less severely affected subjects. Similarly, FVC improvement
was observed even in a shorter period – during ﬁrst 12weeks of
treatment. Important study presented by Gungor et al. [4]
revealed positive impact of the ERT on survival, which was
correlated with improvement of respiratory parameters.
Moreover, regular neurological examination showed im-
provement in muscle strength, however without impact on
reduced tendon reﬂexes. And despite the fact that in no
patient ERT reversed symptoms of the disease totally, initial
improvement followed by long-term stabilization, which
remained during the whole observation period, have signiﬁ-
cant positive impact on quality of life andmaintaining of their
professional activity.
Concluding, similarly to data from other studies [14,15] we
showed that long-term ERT positively affects muscle strength,
pulmonary function, and daily life activities in adult patients
with Pompe disease. The maximal improvement is usually
achieved during the ﬁrst 2 years of treatment.
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